Sesen Bio (SESN): pre income develops a drug for non muscle invasive bladder most cancers remedy. They only received quick monitor approval for his or her lead candidate vicinium and shall be assembly with the FDA for a Biologics License Software later this 12 months. They handed their pre BLA assembly with no additional information requests or security issues.

Presently non muscle invasive bladder most cancers is handled with BCG, a vaccine that’s at the moment present process shortages and was developed 20 years in the past. No drug firm desires to make this product because it has rubbish margins.

There are 75ok new circumstances of bladder most cancers, 70% being non muscle invasive. They might at the moment be handled by BCG vaccine with a 40% nonresponsive price. That is the place Sesens product vicinium is available in. Vicinium is the deliberate alternate to eradicating the bladder and surrounding nodes by way of surgical procedure. This successfully comes right down to roughly 20ok new sufferers handled with vicinium on a yearly foundation. This doesn’t account for multi 12 months sufferers or partial responses to BCG that may nonetheless get remedy by vicinium.

Present market cap is like $150M at slightly below $2 a share

Oncology medication can battle to change into worthwhile when commercialized as a result of there’s a lot cash to be made on this house so it’s usually crowded and it’s a must to promote your remedy methodology to suppliers to advocate over different remedy strategies. Vicinium, Sesns remedy, can be a cease hole between BCG non responders or partial responders and having to have bladder removing surgical procedure.

Aka “Would you like your insurance coverage firm to pay so that you can strive one other drug, or would you like us to skip that step and simply take away your bladder”

Positives:

  1. commercialization in 2020-2021 and substantial income prospects in an beneath met market

  2. being purchased out by large pharma- AstraZeneca companions with them already and will moderately purchase out all the org

Dangers:

  1. not getting approval- 82% of medicine passing pre BLA assembly get approval, so 18% probability of no approval and inventory will get crushed

  2. want funds for commercialization and have an fairness Elevate that dilutes your possession within the quick time period

Supply: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927833/